TY - JOUR
T1 - American Society of Clinical Oncology guideline for antiemetics in oncology
T2 - Update 2006
AU - Kris, Mark G.
AU - Hesketh, Paul J.
AU - Somerfield, Mark R.
AU - Feyer, Petra
AU - Clark-Snow, Rebecca
AU - Koeller, James M.
AU - Morrow, Gary R.
AU - Chinnery, Lawrence W.
AU - Chesney, Maurice J.
AU - Gralla, Richard J.
AU - Grunberg, Steven M.
PY - 2006/6/20
Y1 - 2006/6/20
N2 - Purpose: To update the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology. Update Methodology: The Update Committee completed a review and analysis of data published from 1998 thru February 2006. The literature review focused on published randomized controlled trials, and systematic reviews and meta-analyses of published phase II and phase III randomized controlled trials. Recommendations: The three-drug combination of a 5-hydroxytryptamine-3 (5-HT3) serotonin receptor antagonist, dexamethasone, and aprepitant is recommended before chemotherapy of high emetic risk, For persons receiving chemotherapy of high emetic risk, there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics. These agents should be reserved for patients intolerant of or refractory to 5-HT3 serotonin receptor antagonists, neurokinin-1 receptor antagonists, and dexamethasone. The three-drug combination of a 5-HT3 receptor serotonin antagonist, dexamethasone, and aprepitant is recommended for patients receiving an anthracycline and cyclophosphamide. For patients receiving other chemotherapy of moderate emetic risk, the Update Committee continues to recommend the two-drug combination of a 5-HT3 receptor serotonin antagonist and dexamethasone. In all patients receiving cisplatin and all other agents of high emetic risk, the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis. The Update Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk. Conclusion: The Update Committee recommends that clinicians administer antiemetics while considering patients' emetic risk categories and other characteristics.
AB - Purpose: To update the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology. Update Methodology: The Update Committee completed a review and analysis of data published from 1998 thru February 2006. The literature review focused on published randomized controlled trials, and systematic reviews and meta-analyses of published phase II and phase III randomized controlled trials. Recommendations: The three-drug combination of a 5-hydroxytryptamine-3 (5-HT3) serotonin receptor antagonist, dexamethasone, and aprepitant is recommended before chemotherapy of high emetic risk, For persons receiving chemotherapy of high emetic risk, there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics. These agents should be reserved for patients intolerant of or refractory to 5-HT3 serotonin receptor antagonists, neurokinin-1 receptor antagonists, and dexamethasone. The three-drug combination of a 5-HT3 receptor serotonin antagonist, dexamethasone, and aprepitant is recommended for patients receiving an anthracycline and cyclophosphamide. For patients receiving other chemotherapy of moderate emetic risk, the Update Committee continues to recommend the two-drug combination of a 5-HT3 receptor serotonin antagonist and dexamethasone. In all patients receiving cisplatin and all other agents of high emetic risk, the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis. The Update Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk. Conclusion: The Update Committee recommends that clinicians administer antiemetics while considering patients' emetic risk categories and other characteristics.
UR - http://www.scopus.com/inward/record.url?scp=33745515076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745515076&partnerID=8YFLogxK
U2 - 10.1200/JCO.2006.06.9591
DO - 10.1200/JCO.2006.06.9591
M3 - Review article
C2 - 16717289
AN - SCOPUS:33745515076
SN - 0732-183X
VL - 24
SP - 2932
EP - 2947
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 18
ER -